Page last updated: 2024-10-29

imipramine and Coronary Disease

imipramine has been researched along with Coronary Disease in 11 studies

Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research Excerpts

ExcerptRelevanceReference
"Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect."9.07Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994)
"Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect."5.07Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994)
"The authors report on 12 men with ischemic heart disease who developed secondary depression following myocardial infarction or coronary artery bypass-graft surgery and were treated with imipramine hydrochloride for 4 weeks."3.66Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. ( Barnes, R; Gumbrecht, G; Raskind, M; Veith, R, 1982)
"Amineptine, however, was ineffective in preventing reperfusion arrhythmias even in a high concentration, this agent did not decrease heart rate."1.27Comparison of the effect of antidepressant drugs on arrhythmias in the isolated rat heart subjected to myocardial ischaemia and reperfusion. ( Bril, A; Rochette, L, 1987)
"We evaluated the ability of the Lown arrhythmia grading system to predict death in 400 patients who were convalescing from acute myocardial infarction."1.26Shortcomings of the Lown grading system for observational or experimental studies in ischemic heart disease. ( Bigger, JT; Weld, FM, 1980)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19909 (81.82)18.7374
1990's2 (18.18)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Raskind, M1
Veith, R1
Barnes, R1
Gumbrecht, G1
Zaĭtsev, VP1
Kol'tsova, TI1
Bigger, JT2
Weld, FM2
Cannon, RO1
Quyyumi, AA1
Mincemoyer, R1
Stine, AM1
Gracely, RH1
Smith, WB1
Geraci, MF1
Black, BC1
Uhde, TW1
Waclawiw, MA1
Sparks, DL1
Danner, FW1
Davis, DG1
Hackney, C1
Landers, T1
Coyne, CM1
Biamino, G1
Fenner, H1
Neye, J1
Schuren, KP1
Ramdohr, B1
Krause, EG1
Härtwig, A1
Rabitzsch, G1
Bril, A1
Rochette, L1
Cunescu, V1
Pârvu, V1
Moccetti, T1
Lichtlen, P1
Casaccia, M1
Halter, J1
Mohr, P1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pain Measurement in Healthy Volunteers[NCT00001597]40 participants Observational1997-03-31Completed
Psychophysiological Interactions in Non-Cardiac Chest Pain[NCT00005575]Phase 30 participants Interventional1999-01-31Completed
WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis[NCT00600106]37 participants (Actual)Interventional1999-12-31Completed
A Controlled, Randomized, Double-Blind Trial of Sertraline in Patients With Frontal Lobe Dementia (FLD)[NCT00001777]Phase 130 participants Interventional1997-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Endothelial Dysfunction (FMD)

"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: Baseline

Interventionpercentage of pre-stimulus diameter (Mean)
Hormone Replacement Therapy8.2
Placebo8.8

Endothelial Dysfunction (FMD)

"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: 12 weeks

Interventionpercentage of pre-stimulus diameter (Mean)
Hormone Replacement Therapy8.8
Placebo7.3

Inducible Myocardial Ischemia

Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: 12 weeks

Interventionpercent change in PCR/ATP ratio (Mean)
Hormone Replacement Therapy-7.7
Placebo1.1

Inducible Myocardial Ischemia

Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: Baseline

Interventionpercent changed in PCR/ATP ratio (Mean)
Hormone Replacement Therapy-13.8
Placebo-7.0

Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)

"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Baseline

Interventionmm (Mean)
Hormone Replacement Therapy-0.79
Placebo-0.79

Physical Functional Disability - Functional Capacity (Metabolism Equivalents)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Baseline

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy6.1
Placebo5.8

Physical Functional Disability - Functional Capacity (Metabolism Equivalents)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Exit (12 weeks)

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy6.1
Placebo5.4

Physical Functional Disability - Functional Capacity (METs)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Baseline

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy5.4
Placebo5.4

Physical Functional Disability - Functional Capacity (METs)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Exit at 12 weeks

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy6.1
Placebo5.4

Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)

"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Exit (12 weeks)

Interventionmm (Mean)
Hormone Replacement Therapy-1.05
Placebo-0.63

Quality of Life - Health Survey

"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: 12 weeks

,
Interventionunits on a scale (Mean)
Physical functioningRole-physicalRole-emotionalBodily painGeneral healthMental healthVitalitySocial functioning
Hormone Replacement Therapy59.458.876.554.555.266.435.659.4
Placebo44.425.066.741.557.269.341.256.1

Quality of Life - Health Survey

"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
Physical functioningRole-physicalRole-emotionalBodily painGeneral healthMental healthVitalitySocial functioning
Hormone Replacement Therapy60.854.270.353.355.466.735.659.4
Placebo43.837.366.742.157.465.742.953.2

Quality of Life - Menopause Symptoms

Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: 12 weeks

,
Interventionpercent of participants (Number)
Hot flushes or flashingPoor memoryChange in sexual desireVaginal drynessAvoiding intimacy
Hormone Replacement Therapy4159353524
Placebo8978676756

Quality of Life - Menopause Symptoms

Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: Baseline

,
Interventionpercent of participants (Number)
Hot flushes or flashingPoor memoryChange in sexual desireVaginal drynessAvoiding intimacy
Hormone Replacement Therapy8976504439
Placebo6853375837

Reviews

2 reviews available for imipramine and Coronary Disease

ArticleYear
Drugs and sudden cardiac death.
    Annals of the New York Academy of Sciences, 1982, Volume: 382

    Topics: Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Coronary Disease; Death, Sudden; Diet Fads;

1982
[Drug iatrogenesis in cardiology].
    Medicina interna, 1971, Volume: 23, Issue:1

    Topics: Antidepressive Agents; Antihypertensive Agents; Appetite Depressants; Blood Coagulation Disorders; C

1971

Trials

2 trials available for imipramine and Coronary Disease

ArticleYear
[Comparative effectiveness of tricyclic antidepressants in the treatment of psychic changes in ischemic heart disease].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:5

    Topics: Adult; Affective Symptoms; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as

1980
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994

Other Studies

7 other studies available for imipramine and Coronary Disease

ArticleYear
Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease.
    The American journal of psychiatry, 1982, Volume: 139, Issue:9

    Topics: Adult; Aged; Blood Pressure; Cardiac Complexes, Premature; Coronary Artery Bypass; Coronary Disease;

1982
Shortcomings of the Lown grading system for observational or experimental studies in ischemic heart disease.
    American heart journal, 1980, Volume: 100, Issue:6 Pt 2

    Topics: Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Heart Ventricles; Humans; Imipramine; P

1980
Neurochemical and histopathologic alterations characteristic of Pick's disease in a non-demented individual.
    Journal of neuropathology and experimental neurology, 1994, Volume: 53, Issue:1

    Topics: Acetylcholinesterase; Aged; Brain; Carrier Proteins; Choline O-Acetyltransferase; Cognition; Coronar

1994
Comparative in vitro and in vivo studies on the effects of tricyclic antidepressants on myocardial contractility.
    Recent advances in studies on cardiac structure and metabolism, 1975, Volume: 10

    Topics: Acridines; Animals; Antidepressive Agents, Tricyclic; Cats; Chemical Phenomena; Chemistry; Coronary

1975
On the release of glycogen phosphorylase from heart muscle: effect of substrate depletion, ischemia and of imipramine.
    Biomedica biochimica acta, 1989, Volume: 48, Issue:2-3

    Topics: Animals; Coronary Disease; Creatine Kinase; Glucose; Heart; Imipramine; Insulin; Kinetics; Myocardia

1989
Comparison of the effect of antidepressant drugs on arrhythmias in the isolated rat heart subjected to myocardial ischaemia and reperfusion.
    Pharmacology & toxicology, 1987, Volume: 60, Issue:4

    Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents; Arrhythmias, Cardiac; Coronary Disease; Dibe

1987
[Cardiac toxicity of tricyclic antidepressants].
    Giornale italiano di cardiologia, 1972, Volume: 2, Issue:3

    Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Female; H

1972